Diaceutics Report Sheds Doubt on Pharmas' Personalized Medicine Preparedness | GenomeWeb

Originally published June 14.

By Turna Ray

Researchers in R&D divisions at top drug companies may believe that personalized medicine is the future of therapeutic development, but that sentiment isn't necessarily shared by pharmaceutical execs — a state of affairs that is impeding the investment and infrastructural changes needed to advance the field, a report by Diaceutics has found.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.